MedTrace Logo

Osteogenon in Orthopedics and Traumatology

NCT07210281 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-11-28

No results posted yet for this study

Summary

The aim of this study was to evaluate the supportive effect of the ossein-hydroxyapatite complex in fracture healing. The investigators hypothesized that the ossein-hydroxyapatite complex would positively impact fracture healing outcomes.The assessment covers clinical, radiological and biomechanical parameters.

Conditions

  • Patients With Fractures

Interventions

DRUG

received an ossein-hydroxyapatite complex

Patients in the study group with fractures received an ossein-hydroxyapatite complex (830 mg of ossein-and-hydroxyapatite complex, with 444 mg of hydroxyapatite, equivalent to 178 mg of calcium and 82 mg of phosphorus) throughout the entire period following fracture healing. The tablets were taken orally, one tablet twice daily.

Sponsors & Collaborators

  • University of Opole

    lead OTHER

Principal Investigators

  • Marek Gierlotka, PROF · University of Opole

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2027-02-02
Completion
2027-12-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07210281 on ClinicalTrials.gov